Source link : https://www.newshealth.biz/health-news/fda-oks-new-option-for-rare-immune-mediated-vasculitis/
The FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with polyangiitis (EGPA), drugmaker AstraZeneca announced on Wednesday. EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing vasculitis, extravascular granulomas, and blood and tissue eosinophilia. The rare immune-mediated vasculitis is caused by […]
Author : News Health
Publish date : 2024-09-18 17:17:44
Copyright for syndicated content belongs to the linked Source.
Categories